Momoko Nagai
Overview
Explore the profile of Momoko Nagai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hasegawa S, Shoji Y, Kato M, Elzawahry A, Nagai M, Gi M, et al.
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39456974
Determining a novel etiology and mechanism of human cancer requires extraction of characteristic mutational signatures derived from chemical substances. This study explored the mutational signatures of -nitroso bile acid conjugates...
2.
Nishino T, Yumura M, Sunami K, Kubo T, Ichikawa H, Yasuda T, et al.
Cancer Sci
. 2024 Oct;
115(12):4045-4053.
PMID: 39351646
Accurate estimation of tumor mutational burden (TMB) as a predictor of responsiveness to immune checkpoint inhibitors in gene panel assays requires an adequate panel size. The current calculations of TMB...
3.
Suenaga Y, Kato M, Nagai M, Nakatani K, Kogashi H, Kobatake M, et al.
EMBO Rep
. 2022 Apr;
23(6):e54321.
PMID: 35438231
Recent studies have identified numerous RNAs with both coding and noncoding functions. However, the sequence characteristics that determine this bifunctionality remain largely unknown. In the present study, we develop and...
4.
Oshima K, Kato K, Ito Y, Daiko H, Nozaki I, Nakagawa S, et al.
Cancer Sci
. 2021 Dec;
113(3):1018-1027.
PMID: 34962019
We undertook genomic analyses of Japanese patients with stage I esophageal squamous cell carcinoma (ESCC) to investigate the frequency of genomic alterations and the association with survival outcomes. Biomarker analysis...
5.
Ono H, Arai Y, Furukawa E, Narushima D, Matsuura T, Nakamura H, et al.
BMC Biol
. 2021 Sep;
19(1):207.
PMID: 34548081
Background: Intra-tumor heterogeneity (ITH) encompasses cellular differences in tumors and is related to clinical outcomes such as drug resistance. However, little is known about the dynamics of ITH, owing to...
6.
Mizuno S, Yamaguchi R, Hasegawa T, Hayashi S, Fujita M, Zhang F, et al.
Sci Rep
. 2021 Aug;
11(1):15713.
PMID: 34344966
Immune reactions in the tumor microenvironment are an important hallmark of cancer, and emerging immune therapies have been proven effective against several types of cancers. To investigate cancer genome-immune interactions...
7.
Totsuka Y, Maesako Y, Ono H, Nagai M, Kato M, Gi M, et al.
Proc Jpn Acad Ser B Phys Biol Sci
. 2020 May;
96(5):180-187.
PMID: 32389918
1,4-Dioxane is a genotoxic carcinogen, and its mutagenic properties were recently observed in the liver of guanine phosphoribosyl transferase (gpt) delta transgenic rats. However, the mechanisms of its genotoxicity remain...
8.
Totsuka Y, Lin Y, He Y, Ishino K, Sato H, Kato M, et al.
Chem Res Toxicol
. 2019 Jul;
32(8):1515-1527.
PMID: 31286759
Esophageal cancer is prevalent in Cixian, China, but the etiology of this disease remains largely unknown. Therefore, we explored this by conducting a DNA adductome analysis. Both tumorous and nontumorous...
9.
Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al.
Cancer Sci
. 2019 Feb;
110(4):1480-1490.
PMID: 30742731
Next-generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene aberrations that have diagnostic and therapeutic significance. Here, we undertook a...
10.
Ogura K, Hosoda F, Arai Y, Nakamura H, Hama N, Totoki Y, et al.
Nat Commun
. 2018 Jul;
9(1):2765.
PMID: 30018380
Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate. Here we report the genetic and epigenetic landscape of...